by Usha Govindarajulu | Jan 7, 2022 | Biostatistics, Blog, COVID-19, Healtcare
January 5, 2022 With the ongoing rise in COVID-19 cases due to the Omicron variant of Sars-Cov-2, we searched for some actual studies on the change in vaccine efficacy due to Omicron exposure. In one pre-print article, Buchan et al studied 3,442...
by Usha Govindarajulu | Nov 26, 2021 | Biostatistics, Blog, COVID-19, Healtcare, Professor, Usha Govindarajulu
At home Antigen tests statistical results November 24, 2021 Antigen tests for SARS-CoV-2 are back and are pending more approvals by the current administration. If so, they may be used more often and more frequently to help people get back to a more normal lifestyle....
by Usha Govindarajulu | Nov 10, 2021 | Biostatistics, Blog, Healtcare, Usha Govindarajulu
Pfizer anti-viral November 10, 2021 Pfizer, similar to Merck, has announced the efficacy of their anti-viral drug called PAXLOVID against SARS-CoV-2. The reported 89% efficacy against serious disease and 100% efficacy against death and they are making headlines....
by Usha Govindarajulu | Oct 29, 2021 | Biostatistics, Blog, Usha Govindarajulu
Mix and match boosters October 27, 2021 In recent news, the CDC/FDA are approving booster shots not only for Pfizerã but also for Modernaã and Johnson & Johnsonã, and even mixing and matching these boosters, but is there any science behind this...
by Usha Govindarajulu | Aug 4, 2021 | Biostatistics, Blog, Usha Govindarajulu
As we have heard or know, COVID-19 research, especially in early 2020, was filled with observational studies, many of which were potentially underpowered, but it turns out, even randomized controlled trials. Sample size estimation went out the window. Even Lee...
